Item 2.01. Completion of Acquisition or Disposition of Assets.

On September 21, 2021, PerkinElmer, Inc. (the "Company") filed a Current Report on Form 8-K reporting that on September 17, 2021 the Company, through its direct, wholly owned subsidiaries, Burton Acquisition I, Inc. ("Merger Sub I") and Burton Acquisition II, Inc. (together with Merger Sub I, the "Merger Subs"), completed its acquisition of BioLegend, Inc. ("BioLegend") pursuant to the Agreement and Plan of Merger dated as of July 25, 2021 (the "Merger Agreement") by and among the Company, the Merger Subs, BioLegend and Gene Lay, solely in his capacity as the stockholder representative thereunder.

This Current Report on Form 8-K/A amends the original Form 8-K to provide the historical financial statements of BioLegend required under Item 9.01(a) and the pro forma financial information required under Item 9.01(b).

Item 9.01. Financial Statements and Exhibits.

(a) Financial Statements of Businesses Acquired

The audited consolidated financial statements of BioLegend, Inc. and subsidiaries ("BioLegend") as of and for the year ended December 31, 2020 are filed as Exhibit 99.3 to this Current Report on Form 8-K/A and are incorporated by reference herein. The unaudited condensed consolidated financial statements of BioLegend as of and for the six months ended June 30, 2021 are filed as Exhibit 99.4 to this Current Report on Form 8-K/A and are incorporated by reference herein. The consent of BioLegend's independent auditors is attached hereto as Exhibit 23.1.

(b) Pro Forma Financial Information

The unaudited pro forma condensed combined financial information of the Company and BioLegend for the year ended January 3, 2021 and for the six months ended July 4, 2021 is included as Exhibit 99.5 to this Current Report on Form 8-K/A and is incorporated by reference herein.

--------------------------------------------------------------------------------


(d) Exhibits



Exhibit
  No.                                    Description

2.1(1)        Agreement and Plan of Merger, dated as of July 25, 2021, by and
            among PerkinElmer, Inc., Burton Acquisition I, Inc., Burton
            Acquisition II, Inc., BioLegend, Inc. and Gene Lay, solely in his
            capacity as the Stockholder Representative (incorporated herein by
            reference to Exhibit 2.1 to PerkinElmer, Inc.'s Current Report on Form
            8-K filed with the SEC on July 27, 2021 (File No. 001-05075)).

4.1           Indenture, dated as of October 25, 2011, by and between the Company
            and U.S. Bank National Association (incorporated herein by reference
            to Exhibit 99.1 to the Company's Current Report on Form 8-K filed with
            the SEC on October 27, 2011 (File No. 001-05075)).

4.2           Seventh Supplemental Indenture, dated as of September 10, 2021, by
            and between the Company and U.S. Bank National Association, as trustee
            (including the form of note contained therein) (incorporated herein by
            reference to Exhibit 4.2 to the Company's Current Report on Form 8-K
            filed with the SEC on September 10, 2021 (file No. 001-05075)).

23.1          Consent of Independent Auditors

99.1          Term Loan Credit Agreement, dated as of August 11, 2021, among
            PerkinElmer, Inc., Bank of America, N.A. as Administrative Agent and
            the Lenders party thereto (incorporated herein by reference to Exhibit
            99.1 to PerkinElmer, Inc.'s Current Report on Form 8-K filed with the
            SEC on August 12, 2021 (File No. 001-05075)).

99.2          Credit Agreement, dated as of August 24, 2021, among PerkinElmer,
            Inc., PerkinElmer Health Sciences, Inc., PerkinElmer Life Sciences
            International Holdings, PerkinElmer Global Holdings S.à r.l. and
            PerkinElmer Health Sciences B.V. as Borrowers, Bank of America, N.A.
            as Administrative Agent, Swing Line Lender and an L/C Issuer, the
            Lenders party thereto and the other L/C Issuers party thereto
            (incorporated herein by reference to Exhibit 99.1 to PerkinElmer,
            Inc.'s Current Report on Form 8-K filed with the SEC on August 25,
            2021 (File No. 001-05075)).

99.3          Audited Consolidated Financial Statements of BioLegend, Inc. and
            subsidiaries as of and for the year ended December 31, 2020 and notes
            thereto.

99.4          Unaudited Condensed Consolidated Financial Statements of BioLegend,
            Inc. and subsidiaries as of and for the six months ended June 30, 2021
            and notes thereto.

99.5          Unaudited Pro Forma Condensed Combined Financial Information for the
            year ended January 3, 2021 and for the six months ended July 4, 2021
            and notes thereto.

104         Cover Page Interactive Data File (formatted as inline XBRL with
            applicable taxonomy extension information contained in Exhibit 101)

(1) The exhibits and schedules to the Merger Agreement have been omitted from


    this filing pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees
    to furnish copies of any of such exhibits or schedules to the SEC upon
    request.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses